Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2019) 134 (Supplement_1): 580.

https://doi.org/10.1182/blood-2019-128519

Published: 2019

Journal Articles

Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing

Sarah Haebe, MD, Tanaya Shree, MDPhDBA, Anuja Sathe, PhD, Grady Day, HoJoon Lee, PhD, Debra K. Czerwinski, BA, Susan Grimes, BSc, Hanlee Ji, MD, Ronald Levy, MD

Blood (2019) 134 (Supplement_1): 297.

https://doi.org/10.1182/blood-2019-129445

Published: 2019

Journal Articles

Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM)

Blood (2019) 134 (Supplement_1): 3064.

https://doi.org/10.1182/blood-2019-126527

Published: 2019

Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 3973.

https://doi.org/10.1182/blood-2019-122322

Published: 2019

Journal Articles

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Blood (2019) 134 (Supplement_1): 1752.

https://doi.org/10.1182/blood-2019-128899

Published: 2019

Journal Articles

Carcinocythemia with Microfilaria: Two Diverse Pathologies in One Case

Swagatika Samal, MBBS MD, Shruti Mishra, MBBS, MD PDF Hematology, Rasheeda Mohamedali, MBBS, Kishore Kumar, MBBS, MD DM

Blood (2019) 134 (Supplement_1): 4867.

https://doi.org/10.1182/blood-2019-131393

Published: 2019

Journal Articles

Tumor-educated platelets

Sjors G. J. G. In ‘t Veld, Thomas Wurdinger

Blood (2019) 133 (22): 2359–2364.

https://doi.org/10.1182/blood-2018-12-852830

Published: 2019

Journal Articles

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Sarah K Johnson, PhD, Stephen Burke, PhD, Matthew Henry, M.S., Amy Greenway, Katie Stone, BS, Brian A Walker, PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4466.

https://doi.org/10.1182/blood-2018-99-119241

Published: 2018

Journal Articles

Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations

Adam J Olszewski, MD, Anna Dorota Chorzalska, PhD, Annette S. Kim, MD PhD, Peter J. Quesenberry, MD, Mary L Lopresti, DO, Mary Anne Fenton, MD, John L. Reagan, MD, James Butera, MD, Ilyas Sahin, MD, Celine Hamel, CRA, Jordan Robison, CRA, Max Petersen, Patrycja Dubielecka, PhD

Blood (2018) 132 (Supplement 1): 3841.

https://doi.org/10.1182/blood-2018-99-111436

Published: 2018

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2018) 132 (Supplement 1): 804.

https://doi.org/10.1182/blood-2018-99-117871

Published: 2018

Journal Articles

Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination

Blood (2018) 132 (Supplement 1): 245.

https://doi.org/10.1182/blood-2018-99-113331

Published: 2018

Journal Articles

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Tammie Yeh, PhD, Greg O'Connor, MS, Justin Cidado, PhD, J. Carl Barrett, PhD

Blood (2018) 132 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2018-99-114948

Published: 2018

Journal Articles

Proteomic and Biological Analysis of Myeloma Cell Derived Extracellular Vesicles

Dominique B Hoelzinger, PhD, Sophia J Quinton, Denise K Walters, PhD, Renee C Tschumper, Diane F Jelinek, PhD

Blood (2018) 132 (Supplement 1): 5605.

https://doi.org/10.1182/blood-2018-99-116926

Published: 2018

Journal Articles

Features of the Immunophenotype of Tumor Plasmocytes in the Bone Marrow and Peripheral Blood for Multiple Myeloma Complicated By Plasmacytomas

Kirill Belousov, Anatoly Golenkov, MD, Tatiana Mitina, Yulia Chuksina, Elena Trifonova, MD PhD, Elena Kataeva, MD, Lyudmila Vysotskaya, Yulia Chernykh, Sergei Zakharov, Aleksandr Mitin, Sergei Shevelev, Yulia Sverkunova, Elena Klinushkina

Blood (2017) 130 (Supplement 1): 5334.

https://doi.org/10.1182/blood.V130.Suppl_1.5334.5334

Published: 2017

Journal Articles

DLBCL-Derived Exosomes Provide Key Insights into Genomic Landscape in Cell of Origin and May Lead to a Novel Method of Surveillance and Therapeutic Intervention

Sarah C Rutherford, MD, Angela Fachel, PhD, Sheng Li, PhD, Yanwen Jiang, Maria Pilar Dominguez, PhD, Doron Betel, PhD, Rita Shaknovich, MD PhD

Blood (2017) 130 (Supplement 1): 5132.

https://doi.org/10.1182/blood.V130.Suppl_1.5132.5132

Published: 2017

Journal Articles

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Stefanie Huhn, PhD, Mathias Hänel, MD, Thomas Hielscher, PhD, Uta Bertsch, MD, Hans Jürgen Salwender, Norma Peter, MD, Hartmut Kirchner, Helga Bernhard, MD, Martin Vogel, Ralf Angermund, Martin Goerner, MD, Katja C. Weisel, Jan Duering, Igor W Blau, Niels Weinhold, PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 4359.

https://doi.org/10.1182/blood.V130.Suppl_1.4359.4359

Published: 2017

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma

Mara N Zeissig, BSc, Duncan R. Hewett, BA (Hons), PhD, Sally Martin, PhD, Krzysztof M Mrozik, BSc, Chee Man Cheong, PhD, Peter Diamond, PhD, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Stan Gronthos, PhD, Daniel J Peet, PhD, Peter I Croucher, BSc, PhD, Kate Vandyke, PhD, Andrew C. W. Zannettino, BSc (Hons), PhD

Blood (2017) 130 (Supplement 1): 4425.

https://doi.org/10.1182/blood.V130.Suppl_1.4425.4425

Published: 2017

Journal Articles

Targeted Next Generation Sequencing of Circulating Tumor DNA in Multiple Myeloma

David G. Coffey, MD, Sharon Ornelas, BS, Andrea M.H. Towlerton, BS, Edus H. Warren, III, MDPhD

Blood (2017) 130 (Supplement 1): 4337.

https://doi.org/10.1182/blood.V130.Suppl_1.4337.4337

Published: 2017

Journal Articles

High-throughput sequencing for noninvasive disease detection in hematologic malignancies

Florian Scherer, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2017) 130 (4): 440–452.

https://doi.org/10.1182/blood-2017-03-735639

Published: 2017

NARROW

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing

Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM)

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Carcinocythemia with Microfilaria: Two Diverse Pathologies in One Case

Tumor-educated platelets

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Proteomic and Biological Analysis of Myeloma Cell Derived Extracellular Vesicles

Features of the Immunophenotype of Tumor Plasmocytes in the Bone Marrow and Peripheral Blood for Multiple Myeloma Complicated By Plasmacytomas

DLBCL-Derived Exosomes Provide Key Insights into Genomic Landscape in Cell of Origin and May Lead to a Novel Method of Surveillance and Therapeutic Intervention

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma

Targeted Next Generation Sequencing of Circulating Tumor DNA in Multiple Myeloma

High-throughput sequencing for noninvasive disease detection in hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only